Evidence map›Paper›PMID 38706977›Full record

ArticleJTO clinical and research reports2024

Rapid Response to Lenvatinib and Disease Flare After Discontinuation in a Patient With Thymic Carcinoma Harboring KIT Exon 11 Mutation: A Case Report.

Masahiro Torasawa, Tatsuya Yoshida, Kouya Shiraishi, Naoko Goto, Toshihide Ueno, Hitoshi Ichikawa, Shigehiro Yagishita, Shinji Kohsaka, Yasushi Goto, Yasushi Yatabe and 3 more

Abstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in JTO clinical and research reports, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Masahiro TorasawaDepartment of Thoracic Oncology, National Cancer Center Hospital, Tokyo, Japan.
Tatsuya YoshidaDepartment of Thoracic Oncology, National Cancer Center Hospital, Tokyo, Japan.
Kouya ShiraishiDepartment of Clinical Genomics, National Cancer Center Research Institute, Tokyo, Japan.
Naoko GotoDepartment of Thoracic Oncology, National Cancer Center Hospital, Tokyo, Japan.
Toshihide UenoDivision of Cellular Signaling, National Cancer Center Research Institute, Tokyo, Japan.
Hitoshi IchikawaDepartment of Clinical Genomics, National Cancer Center Research Institute, Tokyo, Japan.
Shigehiro YagishitaDivision of Molecular Pharmacology, National Cancer Center Research Institute, Tokyo, Japan.
Shinji KohsakaDivision of Cellular Signaling, National Cancer Center Research Institute, Tokyo, Japan.
Yasushi GotoDepartment of Thoracic Oncology, National Cancer Center Hospital, Tokyo, Japan.
Yasushi YatabeDepartment of Diagnostic Pathology, National Cancer Center Hospital, Tokyo, Japan.
Akinobu HamadaDivision of Molecular Pharmacology, National Cancer Center Research Institute, Tokyo, Japan.
Hiroyuki ManoDivision of Cellular Signaling, National Cancer Center Research Institute, Tokyo, Japan.
Yuichiro OheDepartment of Thoracic Oncology, National Cancer Center Hospital, Tokyo, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Lenvatinib, a multitarget tyrosine kinase inhibitor for c-Kit and other kinases, has exhibited promising efficacy in treating advanced or metastatic thymic carcinoma (TC). Here, we present the case of a patient with metastatic TC harboring a

Indexed as

Case reportDisease flareLenvatinibThymic carcinoma

Identifiers

PMID38706977
PMCPMC11069009

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.